Sharon E. Altmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sharon E. Altmann has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Alvin L. Smith
Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
1 shared publication- Curtis R. Brandt
Departments of Ophthalmology & Visual Sciences and Medical Microbiology & Immunology, University of Wisconsin, Madison, WI 53706, USA
1 shared publication Jason Paragas
Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, MD 21702, USA
1 shared publication- Joseph E BlaneyJr.
Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick MD, 21702 USA
1 shared publication Joseph E. Blaney
Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
1 shared publicationJulie Dyall
Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, MD 21702, USA
1 shared publication
Latest Publications
- 1 February 2012
- Published by Elsevier in Antiviral Research
- Vol. 93 (2) , 305-308
Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone
- 1 February 2012
- Published by Elsevier in Antiviral Research
- Vol. 93 (2) , 305-308
Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone
- Open Access
- 6 January 2012
- Published by Springer Nature in Virology Journal
- Vol. 9 (1) , 6
Antiviral activity of the EB peptide against zoonotic poxviruses
The EB peptide is a 20-mer that was previously shown to have broad spectrum in vitro activity against several unrelated viruses, including highly pathogenic avian influenza, herpes simplex virus type I, and vaccinia, the prototypic orthopoxvirus. To expand on this work, we evaluated EB for in vitro activity against the zoonotic orthopoxviruses cowpox and monkeypox and for in vivo activity in mice against vaccinia and cowpox.
- 6 January 2012
- Published by Springer Nature in Virology Journal
- Vol. 9 (1) , 6
Open AccessAntiviral activity of the EB peptide against zoonotic poxviruses
The EB peptide is a 20-mer that was previously shown to have broad spectrum in vitro activity against several unrelated viruses, including highly pathogenic avian influenza, herpes simplex virus type I, and vaccinia, the prototypic orthopoxvirus. To expand on this work, we evaluated EB for in vitro activity against the zoonotic orthopoxviruses cowpox and monkeypox and for in vivo activity in mice against vaccinia and cowpox.